Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02677207 | The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive | PHASE2 | COMPLETED | 80 | — | — | Feb 1, 2016 | Jul 1, 2017 | May 22, 2020 | 4 | Moldova, Romania |
Brief Assessment of Cognition (BACS)
| Arm | Type | Description |
|---|---|---|
| JNJ-39393406 | EXPERIMENTAL | 2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial. |
| Placebo | PLACEBO_COMPARATOR | 2 capsules, once daily for the first week and 4 capsules once a day for the rest of the trial. |
| Name | Type | Description |
|---|---|---|
| JNJ-39393406 | DRUG | JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial |
| Placebo | DRUG | JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial |
Inclusion Criteria: 1. Meet DSM V criteria for history of MDD or BPD by MINI. 2. Between 18-50 years of age, male or female subjects of any race, smokers and non-smokers. 3. Able to provide informed consent. All participant patients must have signed an informed consent document indicating they unde...